Serum levels of ubiquitin C-terminal hydrolase distinguish mild traumatic brain injury from trauma controls and are elevated in mild and moderate traumatic brain injury patients with intracranial lesions and neurosurgical intervention.
about
Biomarkers of Brain Damage and Postoperative Cognitive Disorders in Orthopedic Patients: An UpdateIdentification of serum microRNA signatures for diagnosis of mild traumatic brain injury in a closed head injury model.Combining biochemical and imaging markers to improve diagnosis and characterization of mild traumatic brain injury in the acute setting: results from a pilot studyHigh interindividual variability in dose-dependent reduction in speed of movement after exposing C. elegans to shock waves.Assessing neuro-systemic & behavioral components in the pathophysiology of blast-related brain injury.What's New in Traumatic Brain Injury: Update on Tracking, Monitoring and TreatmentPotential Blood-based Biomarkers for Concussion.Biomarkers and acute brain injuries: interest and limitsMilitary personnel with chronic symptoms following blast traumatic brain injury have differential expression of neuronal recovery and epidermal growth factor receptor genes.A novel, ultrasensitive assay for tau: potential for assessing traumatic brain injury in tissues and biofluids.Ubiquitin carboxy-terminal hydrolase-l1 as a serum neurotrauma biomarker for exposure to occupational low-level blastConcussion guidelines step 1: systematic review of prevalent indicators.Multivariate analysis of traumatic brain injury: development of an assessment score.Measurement of the glial fibrillary acidic protein and its breakdown products GFAP-BDP biomarker for the detection of traumatic brain injury compared to computed tomography and magnetic resonance imaging.Systematic review of clinical studies examining biomarkers of brain injury in athletes after sports-related concussion.Biomarkers of mild traumatic brain injury in cerebrospinal fluid and bloodThe diagnosis of traumatic brain injury on the battlefield.A Role of Serum-Based Neuronal and Glial Markers as Potential Predictors for Distinguishing Severity and Related Outcomes in Traumatic Brain Injury.Autoimmune Profiling Reveals Peroxiredoxin 6 as a Candidate Traumatic Brain Injury BiomarkerH-FABP: A new biomarker to differentiate between CT-positive and CT-negative patients with mild traumatic brain injury.Current status of fluid biomarkers in mild traumatic brain injuryAbility of Serum Glial Fibrillary Acidic Protein, Ubiquitin C-Terminal Hydrolase-L1, and S100B To Differentiate Normal and Abnormal Head Computed Tomography Findings in Patients with Suspected Mild or Moderate Traumatic Brain Injury.Therapy development for diffuse axonal injury.Assessment of Serum UCH-L1 and GFAP in Acute Stroke Patients.A military-centered approach to neuroprotection for traumatic brain injury.Plasma Anti-Glial Fibrillary Acidic Protein Autoantibody Levels during the Acute and Chronic Phases of Traumatic Brain Injury: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot Study.GFAP-BDP as an acute diagnostic marker in traumatic brain injury: results from the prospective transforming research and clinical knowledge in traumatic brain injury study.Glycosylation and other PTMs alterations in neurodegenerative diseases: Current status and future role in neurotrauma.Utility of neuron-specific enolase in traumatic brain injury; relations to S100B levels, outcome, and extracranial injury severity.Evidence That the Blood Biomarker SNTF Predicts Brain Imaging Changes and Persistent Cognitive Dysfunction in Mild TBI PatientsAcute biomarkers of traumatic brain injury: relationship between plasma levels of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein.A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury.Biomarkers for the clinical differential diagnosis in traumatic brain injury--a systematic review.The challenge of mild traumatic brain injury: role of biochemical markers in diagnosis of brain damage.Monitoring biomarkers of cellular injury and death in acute brain injury.Consensus summary statement of the International Multidisciplinary Consensus Conference on Multimodality Monitoring in Neurocritical Care: a statement for healthcare professionals from the Neurocritical Care Society and the European Society of IntenProspective Assessment of Acute Blood Markers of Brain Injury in Sport-Related Concussion.Biomarkers of Traumatic Brain Injury: Temporal Changes in Body FluidsPerspectives on molecular biomarkers of oxidative stress and antioxidant strategies in traumatic brain injury.Role of Systems Biology in Brain Injury Biomarker Discovery: Neuroproteomics Application.
P2860
Q26784577-3CE0EBAC-AF28-4C0B-A915-47FEC40A5FAFQ27331576-48657F69-1174-4561-B642-1B09F7D16AB4Q28535264-99462AAE-261E-4953-A466-6DD3E12E795AQ30418386-4FDC1C39-2501-46E0-8CA1-046326F1C1D1Q30446201-2BA69EA8-CD5E-4355-8775-39FBDDBD5B11Q30959630-BDCC8B5D-0E6B-45FE-A0B7-1815837201CBQ31119100-1B7753A6-A09B-443A-BCDA-907BE4E28076Q33752053-F44738A9-C5CE-4CC3-8420-B7883B0E5468Q34312203-8FB3FA95-E602-4F6F-900D-ED43E8E232D6Q35142344-3A156328-CB19-49AC-B2FC-E98371CA14F2Q35179591-6AA8306C-57C8-4E0E-B906-00F3E2D33087Q35203701-33ED5B8D-D70D-4424-AD92-0CF5D521CBF4Q35229002-DC977D23-E85A-48B5-B095-254125278CFAQ35376450-4F0B270A-583C-47FF-BB70-8D1B10F61920Q35589772-0DEF0736-2E88-419C-BBE3-1D7CBF90601AQ35885458-75543C96-D2F3-4E1E-8532-2EE632EB53E3Q36026050-7E454E3D-DABB-422C-A08D-59D567B5D5C3Q36044131-957FB744-8226-4342-BD9E-7074807A4EEFQ36294820-FC71F70D-D3E4-45D5-BE93-371FEEE021B0Q36349690-05B0859B-7E3B-4F0A-9599-D1FE84A1E69EQ36424343-58CDA770-F495-423A-B841-006DB8ECEAA1Q36489525-21F71173-0321-4CBD-A27B-E1ED906AEF40Q36768885-B80EAA3A-BD85-4F13-ACC5-72A53811DDFAQ36796090-8EAAE787-95C3-4F56-AB36-C0463B0CFB91Q36920836-8DF29CA5-8989-4A78-BFF2-E6DF109B9203Q37061236-55BE8130-3308-4C4B-ABCC-D8E9DC8F3C5DQ37115239-1F629C31-341C-483F-A9C1-FC6E7E4FD2C2Q37130046-AC5E4251-6C9F-4E1D-A4DA-AE43DEA15757Q37240562-36BFED9B-61AB-44CC-83F6-D525027CC462Q37317257-0CC870A0-D9BC-41D3-9D9E-62ACE6B330A6Q37430560-E3DC9CCA-421B-4252-A27F-E9CD7EF60AD2Q37590627-4180A6F7-1FA0-4AC4-82F9-DDC3A7FBD2E4Q38109663-382A8B70-B795-49ED-B2B2-55AA3EE07DCFQ38118282-19138BBD-E65D-4126-ADDF-FF19A04D1B51Q38248158-86607426-FEFD-49A1-B341-CEEB3D4539F6Q38248160-7003F1BD-E5D1-46FA-BD92-4B5472A0C79DQ38658776-3A93A134-F278-4BED-B38F-5D57280CDF03Q39061827-AAA580AC-0DA6-432D-94AA-23443B65D52FQ39218449-B2CB0CF2-47FF-458D-A06C-5CBF0704CDAFQ39413066-6263E716-BF4A-497B-85B2-BFD3DBFBEA40
P2860
Serum levels of ubiquitin C-terminal hydrolase distinguish mild traumatic brain injury from trauma controls and are elevated in mild and moderate traumatic brain injury patients with intracranial lesions and neurosurgical intervention.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Serum levels of ubiquitin C-te ...... nd neurosurgical intervention.
@ast
Serum levels of ubiquitin C-te ...... nd neurosurgical intervention.
@en
type
label
Serum levels of ubiquitin C-te ...... nd neurosurgical intervention.
@ast
Serum levels of ubiquitin C-te ...... nd neurosurgical intervention.
@en
prefLabel
Serum levels of ubiquitin C-te ...... nd neurosurgical intervention.
@ast
Serum levels of ubiquitin C-te ...... nd neurosurgical intervention.
@en
P2093
P2860
P50
P1476
Serum levels of ubiquitin C-te ...... nd neurosurgical intervention.
@en
P2093
Claudia S Robertson
Frank C Tortella
Jason A Demery
Jay L Falk
Jixiang Mo
Kara Schmid
Lawrence M Lewis
Linda Papa
Linnet Akinyi
Ming Cheng Liu
P2860
P304
P356
10.1097/TA.0B013E3182491E3D
P577
2012-05-01T00:00:00Z